vs
雅培（ABT）与Arcellx, Inc.（ACLX）财务数据对比。点击上方公司名可切换其他公司
雅培的季度营收约是Arcellx, Inc.的6928.1倍（$11.5B vs $1.7M）。雅培净利率更高（15.5% vs -3513.4%，领先3528.9%）。雅培同比增速更快（4.4% vs -89.2%）。雅培自由现金流更多（$2.6B vs $-58.9M）。过去两年雅培的营收复合增速更高（7.2% vs -79.5%）
雅培是总部位于美国伊利诺伊州雅培园的跨国医疗健康企业，业务覆盖美国境外市场药品销售、诊断产品、营养产品及医疗器械等板块，在全球医疗健康领域拥有较高的行业知名度与广泛的市场覆盖。
Arcellx, Inc.是一家处于临床阶段的生物技术企业，专注开发用于治疗血液恶性肿瘤、实体瘤等难治性癌症的CAR-T细胞疗法，其核心管线针对肿瘤领域未被满足的医疗需求，服务全球患者群体。
ABT vs ACLX — 直观对比
营收规模更大
ABT
是对方的6928.1倍
$1.7M
营收增速更快
ABT
高出93.6%
-89.2%
净利率更高
ABT
高出3528.9%
-3513.4%
自由现金流更多
ABT
多$2.7B
$-58.9M
两年增速更快
ABT
近两年复合增速
-79.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $11.5B | $1.7M |
| 净利润 | $1.8B | $-58.1M |
| 毛利率 | 57.0% | — |
| 营业利润率 | 19.6% | -3850.2% |
| 净利率 | 15.5% | -3513.4% |
| 营收同比 | 4.4% | -89.2% |
| 净利润同比 | -80.8% | -23.4% |
| 每股收益（稀释后） | $1.01 | $-1.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABTACLX
| Q4 25 | $11.5B | $1.7M | ||
| Q3 25 | $11.4B | $4.9M | ||
| Q2 25 | $11.1B | $7.6M | ||
| Q1 25 | $10.4B | $8.1M | ||
| Q4 24 | $11.0B | $15.3M | ||
| Q3 24 | $10.6B | $26.0M | ||
| Q2 24 | $10.4B | $27.4M | ||
| Q1 24 | $10.0B | $39.3M |
净利润ABTACLX
| Q4 25 | $1.8B | $-58.1M | ||
| Q3 25 | $1.6B | $-55.8M | ||
| Q2 25 | $1.8B | $-52.8M | ||
| Q1 25 | $1.3B | $-62.3M | ||
| Q4 24 | $9.2B | $-47.1M | ||
| Q3 24 | $1.6B | $-25.9M | ||
| Q2 24 | $1.3B | $-27.2M | ||
| Q1 24 | $1.2B | $-7.2M |
毛利率ABTACLX
| Q4 25 | 57.0% | — | ||
| Q3 25 | 55.4% | — | ||
| Q2 25 | 56.4% | — | ||
| Q1 25 | 56.9% | — | ||
| Q4 24 | 55.0% | — | ||
| Q3 24 | 55.8% | — | ||
| Q2 24 | 55.6% | — | ||
| Q1 24 | 55.2% | — |
营业利润率ABTACLX
| Q4 25 | 19.6% | -3850.2% | ||
| Q3 25 | 18.1% | -1248.3% | ||
| Q2 25 | 18.4% | -777.4% | ||
| Q1 25 | 16.3% | -847.6% | ||
| Q4 24 | 17.4% | -348.2% | ||
| Q3 24 | 17.5% | -129.1% | ||
| Q2 24 | 16.1% | -127.8% | ||
| Q1 24 | 13.9% | -40.3% |
净利率ABTACLX
| Q4 25 | 15.5% | -3513.4% | ||
| Q3 25 | 14.5% | -1127.1% | ||
| Q2 25 | 16.0% | -698.6% | ||
| Q1 25 | 12.8% | -766.0% | ||
| Q4 24 | 84.1% | -308.4% | ||
| Q3 24 | 15.5% | -99.4% | ||
| Q2 24 | 12.5% | -99.3% | ||
| Q1 24 | 12.3% | -18.3% |
每股收益（稀释后）ABTACLX
| Q4 25 | $1.01 | $-1.01 | ||
| Q3 25 | $0.94 | $-0.99 | ||
| Q2 25 | $1.01 | $-0.94 | ||
| Q1 25 | $0.76 | $-1.13 | ||
| Q4 24 | $5.26 | $-0.87 | ||
| Q3 24 | $0.94 | $-0.48 | ||
| Q2 24 | $0.74 | $-0.51 | ||
| Q1 24 | $0.70 | $-0.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.9B | $450.3M |
| 总债务越低越好 | $12.9B | — |
| 股东权益账面价值 | $52.1B | $402.4M |
| 总资产 | $86.7B | $604.0M |
| 负债/权益比越低杠杆越低 | 0.25× | — |
8季度趋势，按日历期对齐
现金及短期投资ABTACLX
| Q4 25 | $8.9B | $450.3M | ||
| Q3 25 | $7.7B | $461.4M | ||
| Q2 25 | $7.3B | $453.1M | ||
| Q1 25 | $6.8B | $543.3M | ||
| Q4 24 | $8.0B | $587.4M | ||
| Q3 24 | $7.8B | $574.3M | ||
| Q2 24 | $7.2B | $516.7M | ||
| Q1 24 | $6.7B | $573.9M |
总债务ABTACLX
| Q4 25 | $12.9B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $14.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ABTACLX
| Q4 25 | $52.1B | $402.4M | ||
| Q3 25 | $51.0B | $440.8M | ||
| Q2 25 | $50.6B | $392.2M | ||
| Q1 25 | $48.8B | $416.9M | ||
| Q4 24 | $47.7B | $454.8M | ||
| Q3 24 | $39.8B | $483.0M | ||
| Q2 24 | $39.3B | $487.2M | ||
| Q1 24 | $38.8B | $496.6M |
总资产ABTACLX
| Q4 25 | $86.7B | $604.0M | ||
| Q3 25 | $84.2B | $655.9M | ||
| Q2 25 | $84.0B | $619.1M | ||
| Q1 25 | $81.4B | $648.1M | ||
| Q4 24 | $81.4B | $711.3M | ||
| Q3 24 | $74.4B | $764.9M | ||
| Q2 24 | $73.0B | $734.3M | ||
| Q1 24 | $72.5B | $779.7M |
负债/权益比ABTACLX
| Q4 25 | 0.25× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.30× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.3B | $-58.2M |
| 自由现金流经营现金流 - 资本支出 | $2.6B | $-58.9M |
| 自由现金流率自由现金流/营收 | 22.9% | -3563.4% |
| 资本支出强度资本支出/营收 | 6.0% | 46.2% |
| 现金转化率经营现金流/净利润 | 1.87× | — |
| 过去12个月自由现金流最近4个季度 | $7.4B | $-212.6M |
8季度趋势，按日历期对齐
经营现金流ABTACLX
| Q4 25 | $3.3B | $-58.2M | ||
| Q3 25 | $2.8B | $-49.2M | ||
| Q2 25 | $2.0B | $-39.7M | ||
| Q1 25 | $1.4B | $-63.1M | ||
| Q4 24 | $2.9B | $-46.0M | ||
| Q3 24 | $2.7B | $30.7M | ||
| Q2 24 | $2.0B | $-36.2M | ||
| Q1 24 | $1.0B | $-31.9M |
自由现金流ABTACLX
| Q4 25 | $2.6B | $-58.9M | ||
| Q3 25 | $2.3B | $-49.5M | ||
| Q2 25 | $1.5B | $-40.2M | ||
| Q1 25 | $933.0M | $-63.9M | ||
| Q4 24 | $2.1B | $-47.5M | ||
| Q3 24 | $2.1B | $28.4M | ||
| Q2 24 | $1.4B | $-39.5M | ||
| Q1 24 | $627.0M | $-38.3M |
自由现金流率ABTACLX
| Q4 25 | 22.9% | -3563.4% | ||
| Q3 25 | 20.2% | -1000.3% | ||
| Q2 25 | 13.9% | -532.4% | ||
| Q1 25 | 9.0% | -786.4% | ||
| Q4 24 | 19.6% | -311.3% | ||
| Q3 24 | 20.2% | 109.2% | ||
| Q2 24 | 13.8% | -144.1% | ||
| Q1 24 | 6.3% | -97.7% |
资本支出强度ABTACLX
| Q4 25 | 6.0% | 46.2% | ||
| Q3 25 | 4.4% | 6.0% | ||
| Q2 25 | 4.5% | 6.4% | ||
| Q1 25 | 4.7% | 9.6% | ||
| Q4 24 | 6.6% | 9.8% | ||
| Q3 24 | 5.2% | 8.8% | ||
| Q2 24 | 5.1% | 11.7% | ||
| Q1 24 | 4.0% | 16.4% |
现金转化率ABTACLX
| Q4 25 | 1.87× | — | ||
| Q3 25 | 1.70× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 1.64× | — | ||
| Q2 24 | 1.51× | — | ||
| Q1 24 | 0.84× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
